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A systematic review and narrative synthesis of
data-driven studies in schizophrenia symptoms
and cognitive deficits
Tesfa Dejenie Habtewold 1,2, Lyan H. Rodijk1,3, Edith J. Liemburg2, Grigory Sidorenkov1, H. Marike Boezen1,
Richard Bruggeman2,4 and Behrooz Z. Alizadeh 1,2
Abstract
To tackle the phenotypic heterogeneity of schizophrenia, data-driven methods are often applied to identify subtypes
of its symptoms and cognitive deficits. However, a systematic review on this topic is lacking. The objective of this
review was to summarize the evidence obtained from longitudinal and cross-sectional data-driven studies in positive
and negative symptoms and cognitive deficits in patients with schizophrenia spectrum disorders, their unaffected
siblings and healthy controls or individuals from general population. Additionally, we aimed to highlight
methodological gaps across studies and point out future directions to optimize the translatability of evidence from
data-driven studies. A systematic review was performed through searching PsycINFO, PubMed, PsycTESTS,
PsycARTICLES, SCOPUS, EMBASE and Web of Science electronic databases. Both longitudinal and cross-sectional
studies published from 2008 to 2019, which reported at least two statistically derived clusters or trajectories were
included. Two reviewers independently screened and extracted the data. In this review, 53 studies (19 longitudinal and
34 cross-sectional) that conducted among 17,822 patients, 8729 unaffected siblings and 5520 controls or general
population were included. Most longitudinal studies found four trajectories that characterized by stability, progressive
deterioration, relapsing and progressive amelioration of symptoms and cognitive function. Cross-sectional studies
commonly identified three clusters with low, intermediate (mixed) and high psychotic symptoms and cognitive
profiles. Moreover, identified subgroups were predicted by numerous genetic, sociodemographic and clinical factors.
Our findings indicate that schizophrenia symptoms and cognitive deficits are heterogeneous, although
methodological limitations across studies are observed. Identified clusters and trajectories along with their predictors
may be used to base the implementation of personalized treatment and develop a risk prediction model for high-risk
individuals with prodromal symptoms.
Introduction
In psychiatry, phenotypic heterogeneity of disorders and
their overlapping symptoms that may presumably share
some fundamental biologic underpinnings is a major
challenge for tailoring individualized therapies1. Similarly,
the course and phenotypic expression of schizophrenia
are variable2. Schizophrenia is a complex polygenic psy-
chotic disorder with a lifetime morbidity risk of 0.7%3.
The twin- and SNP-based heritability estimate of schi-
zophrenia was 80%4 and 30%5, respectively.
According to the diagnostic and statistical manual of
mental disorders (DSM) criteria, the clinical manifesta-
tions of schizophrenia are positive (e.g., hallucinations,
delusions and disorganized behaviour) and negative (e.g.,
emotional expressive deficit, social amotivation, social
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withdrawal and difficulty in experiencing pleasure)
symptoms6. Cognitive deficit is also one of the hallmark
manisfestations of schizophrenia that occur in 75–80% of
patients and often associated with poor daily functioning
and quality of life7. Cognitive impairment in schizo-
phrenia can be selective or general though the most
common deficits occur in executive function, processing
speed, memory (e.g. episodic, verbal and working),
attention, verbal fluency, problem-solving and social
cognition8–11. Patients harbor a wide range of subjectively
defined symptoms, which together yields instinctively
heterogeneous groups of people who are collectively
diagnosed with schizophrenia. Subclinical or prodromal
symptoms are also evident in relatives of patients with
schizophrenia and healthy general population12–14.
Despite a century of efforts, understanding the hetero-
geneity in the clinical presentation and course of schizo-
phrenia has been unsuccessful. This can be due to the
subjective measurement of its clinical symptoms, varia-
tion in response to treatment, lack of valid, stable, and
meaningful sub-phenotyping methods, and molecular
complexity with limited understanding of the pathophy-
siology15–17. Phenotypic heterogeneity can be related to
several intrinsic and extrinsic factors and expressed in
patients, time, and disease sub-phenotypes16,18. Identifi-
cation of meaningful homogeneous subgroups of people
based on their symptoms or endophenotypes (e.g. neu-
ropsychological markers, neural substrates, and neurolo-
gical soft signs) requires the use of both supervised and
unsupervised analyses. Distinguishing heterogeneous
patients to more behaviorally and biologically similar
subgroups is expedient not only to unveil common
etiologies but also to examine the patterns of clinical
symptoms, understand the biology of disease, predict
treatment response and develop a new targeted treatment
that improves recovery and functional outcomes15,16,19,20.
For tackling heterogeneity, in the past decade, numerous
efforts have been undertaken by carefully designing studies
and developing statistical models implemented in various
programming languages and software16. In 2013, the
American Psychiatric Association also endorsed a dimen-
sional approach to identify intermediate categories based on
the subjective report of severity of symptoms6. As a result,
researchers have been using latent class cluster analyses and
growth mixture models to explore clusters of individuals and
trajectories of clinical symptoms in various settings15,21,22.
Statistical methods can be used to identify subgroups and
describe within and between individual variations to guide
clinicians and statisticians to explore the relationship of
diseases with various clinical and functional outcomes,
treatment response, and neuropathological change. More-
over, subtyping using imaging, biological and symptom data
is a recognizable method and widely used in psychiatric
research21.
Several reviews have been conducted on positive
symptoms23, negative symptoms24–26 and cognitive dys-
function7,9,27–35. However, these reviews have largely
focused on the conventional approach for determining an
average change in the course of symptoms over time and
the difference between subjects (e.g., patient vs sibling,
sibling vs control, or patient vs control) and diagnosis.
Reviewed studies are also based on correlation analysis,
which is believed not to be a strong measure of associa-
tion between predictors and outcomes36. Besides, these
primary studies vary in terms of study population and use
of assessment tools, scoring and standardization techni-
ques, and have several limitations, such as small sample
size, short duration of follow-up and limited use of data
from healthy siblings and/or controls9,37,38. Of interest,
none of these reviews fully addressed evidence from both
longitudinal and cross-sectional data-driven studies on
schizophrenia symptoms and cognitive deficits among
patients with schizophrenia spectrum disorders, relatives
and healthy controls. Taken together, thus far, our
understanding of the heterogeneity of the course of
schizophrenia symptoms and cognitive deficits is still lim-
ited. In the present systematic review, we summarized the
contemporary evidence from cross-sectional and long-
itudinal studies on positive and negative symptoms and
cognitive deficits among patients with schizophrenia spec-
trum disorders, their unaffected siblings and healthy peo-
ple. Additionally, we explored the extent and origin of
heterogeneity across studies. We further highlighted com-
mon methodological gaps and point out future directions
to optimize the translatability of evidence from data-driven
studies within the outlook of a personalized approach.
Methods
Registration and reporting
This systematic review was conducted and reported
based on a registered protocol39 and the Preferred
Reporting Items for Systematic Review and Meta-Analysis
(PRISMA) statement (Supplementary File 1), respec-
tively40,41. The screening and selection process of the
reviewed articles are further illustrated using a PRISMA
flow diagram.
Databases and search terms
A systematic search of PubMed, PsycINFO, PsycTESTS,
PsycARTICLES, SCOPUS, EMBASE and Web of Science
electronic databases was performed. A comprehensive
search strategy was developed for PubMed and adapted
for each database in consultation with a medical infor-
mation specialist (Supplementary File 2). The following
search terms were used in their singular or plural form in
the title, abstract, keywords and text fields of the articles:
“schizophrenia”, “psychosis”, “non-affective psychosis”,
“cognitive deficit”, “cognitive dysfunction”, “cognitive
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alteration”, “negative symptoms”, “deficit syndrome”,
“positive symptoms”, “psychopathology”, “cognit*”, “neu-
ropsycholog*”, “neurocognition”, “longitudinal”, “follow-
up”, “course”, “heterogeneity”, “endophenotype”, “profile”,
“cluster analysis”, “siblings”, “healthy controls”, “latent
class analyses”, “Symptom trajectories”, “traject*”, “group
modelling” and “trajectory”. Cross-references of included
articles and grey literature were also hand-searched.
Furthermore, we searched the table of contents of the
journals of Schizophrenia Research, Schizophrenia Bul-
letin, Acta Psychiatrica Scandinavica, BMC Psychiatry,
American Journal of Psychiatry and British Journal of
Psychiatry to explore relevant studies. The freezing date
for the final search was August 2019. In this review, we
use ‘trajectory’ for groups identified in longitudinal studies
and “cluster” for groups identified in cross-sectional
studies.
Inclusion and exclusion criteria
Studies which met the following criteria were included:
(1) longitudinal and cross-sectional studies; (2) studies
that reported at least two clusters or trajectory groups of
individuals using a statistical method based on a distinct
positive symptom, negative symptom, and cognitive def-
icit or a combination of these symptoms; (3) studies
conducted in patients with schizophrenia spectrum dis-
orders, unaffected relatives, or healthy individuals irre-
spective of their clinical (e.g. medication status, severity of
illness) and sociodemographic characteristics; and (4)
studies published in English from 2008 to 2020. The
publication year was limited to the last decade to capture
the latest available evidence, which is likely to provide
statistically powerful estimates and successfully subtyping
schizophrenia symptoms given the increased number of
large cohorts. To maximize the number of searched
articles, the follow-up period in longitudinal studies was
not restricted. Longitudinal studies based on the analyses
of the mean levels of change of symptom scores were
excluded because they did not capture individuals’ pat-
terns of change over time by treating between-subject
variation as an error, so that the actual heterogeneity of
groups cannot be revealed42. Also, studies based on the
non-statistical methods of clustering (e.g. family-based
clustering) were excluded. Review papers, commentaries,
conference abstracts, duplicate studies, editorials, and
qualitative studies were excluded as well. Furthermore, we
excluded studies in which the trajectory groups or clusters
were generated based on scores constructed using a
combination of schizophrenia symptoms and other
unspecified psychotic symptoms.
Data retrieval and synthesis
Studies retrieved from all databases were exported to
RefWorks version 2.0 for Windows web-based citation
manager, which followed by the removal of close and
exact duplicates. All independent studies were exported to
a Microsoft Excel spreadsheet to screen for further
inclusion criteria. Authors T.D.H. and L.H.R. indepen-
dently screened the titles and abstracts. The two reviewers
had a substantial agreement (Kappa statistic (κ)= 0.62).
Inconsistent decisions were discussed and solved with
consensus. Finally, full-text was reviewed, and the fol-
lowing data were independently extracted by T.D.H. and
L.H.R.: first author name, publication year, country,
cohort/research center, study population, sample size,
symptom dimension(s), assessment tool, study design,
duration of follow-up for longitudinal studies, frequency
of assessment, method of calculating composite score,
method of clustering/trajectory analysis, number of iden-
tified clusters or trajectory groups and significant correlates
of clusters and predictors of trajectories43. The corre-
sponding author was contacted by email if the full-text of
included article was not accessible. When studies did not
report the cohort or research center, we extracted the
institutional affiliation of the first or corresponding author.
Results
Search results
In total, 2262 articles were identified through database
searching and an additional 26 articles were obtained
through manual searching of cross-references and tables
of content of relevant journals. After removing duplicate
and unrelated articles, the titles and abstracts of 1292
articles were screened. The evaluation of titles and
abstracts resulted in the exclusion of 1231 articles. In
total, 61 articles were selected for full-text review, and
eight articles44–51 were excluded due to unclear outcomes,
mixed diagnosis of the study population and use of a non-
statistical method of clustering or clustering based on
different phenotypes of schizophrenia. Finally, data were
extracted from 53 longitudinal and cross-sectional stu-
dies. The PRISMA flow diagram of screening and the
selection process is shown in Fig. 1.
Overview of included studies
The included 53 studies were conducted globally in 30
countries and published over a decade from 2009 to 2020.
Seventeen studies were conducted in the USA and few
studies were internationally conducted. Of these, 19 stu-
dies were longitudinal that involved 11,684 patients,
1059 siblings and 2194 controls or general population
from more than eight countries, whereas 34 studies were
cross-sectional that involved 6138 patients, 7670 siblings,
and 3326 controls from 14 countries. Most of the long-
itudinal studies examined trajectories of positive and
negative symptoms in patients, whereas most of the cross-
sectional studies explored cognitive subtypes in patients.
Only one longitudinal study52 and three cross-sectional
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studies53–55 examined cognitive subtypes among siblings.
Overall, two to six subtypes of positive and negative
symptoms and cognitive deficits were identified.
Longitudinal studies
In total, 19 longitudinal studies were reviewed that
included all population age groups with the duration of
follow-up ranged from six weeks to 10 years. The sample
size ranged from 138 to 1990 subjects. Even though all
studies had a similar aim, they have used slightly different
models of trajectory analysis and model selection criteria.
Growth mixture modelling (GMM)17,56,57, latent class
growth analysis (LCGA)16,19,20,58–61, mixed-mode latent
class regression modelling22,62,63, group-based trajectory
modelling (GBTM)52,64–66 and Ward’s method67 were
reported data-driven methods. Akaike’s Information Cri-
terion (AIC), Bayesian information criterion (BIC) (i.e.,
used in most studies), deviance information criterion
(DIC), logged Bayes factor, sample size adjusted BIC
(aBIC), bootstrap likelihood ratio test [BLRT], Gap sta-
tistic, Lo–Mendell–Rubin Likelihood Ratio Test (LMR-
LRT) and entropy were reported model selection indices.
Most longitudinal studies, Table 1, investigated the tra-
jectory of positive, negative or both symptoms in patients
whereas one study68 explored the trajectory of schizotypy in a
nonclinical population. Another study57 examined the asso-
ciation between positive and negative symptom trajectories
in patients. Moreover, three studies examined the long-term
trajectories of cognitive impairment in patients, their unaf-
fected siblings and healthy controls16,52,66. One study52
investigated the association between patients’ and siblings’
cognitive trajectories as well. Overall, these studies char-
acterized the general pattern of identified trajectories as
progressive deterioration, relapsing, progressive amelioration
and stable, and the detail results are presented per symptom
domains as follows.
Positive symptoms
As presented in Table 1a, four studies19,20,57,65 investi-
gated the trajectory of positive symptoms in patients with
first-episode schizophrenia spectrum disorders with no or
prior antipsychotics treatment for less than three months.
The duration of follow-up and frequency of assessment
ranged from six weeks to 10 years and five to seven times,
respectively. Two studies19,65 have used the Scale for the
Assessment of Positive Symptoms (SAPS) to assess posi-
tive symptoms and identified five trajectories with more
than one-third of patients subtyped as decrease positive
symptoms or good responders. The other two studies
used the Positive and Negative Syndrome Scale (PANSS)
Articles identified through 
database searching 
(n = 2,262)
Additional articles identified 
through manual searching
(n = 26)
Articles after duplicates 
removed
(n = 1,317)
Articles title and abstract 
screened 
(n = 1,292)
Full-text articles assessed for 
further eligibility (n = 61)
Studies included in systematic 
review (n =   53)
Unrelated articles excluded
(n = 25)
Articles excluded based on 
inclusion and exclusion criteria
(n = 1,231)
Full-text articles excluded with 
reasons (n = 8)
Fig. 1 PRISMA flow diagram illustrating the screening and selection of literature.
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tool to assess positive symptoms and identified three
trajectories that most of them grouped to class two57 and
two trajectories being in the most of the cases early
response and stable trajectory over time20. The identified
predictors were male gender, low educational status,
substance use, diagnosis with schizophrenia, long dura-
tion of untreated psychosis, poor global functioning, and
severe baseline positive and negative symptoms (Fig. 2).
Negative symptoms
Eight longitudinal studies19,20,57,58,61,64,65,67 explored
negative symptom trajectories among patients with first-
episode non-affective psychosis with no prior or minimal
treatment up to three months (Table 1b). Two studies19,65
used the Scale for the Assessment of Negative Symptoms
(SANS), four studies20,57,61,64 used the PANSS scale and
two studies used the High Royds Evaluation of Negativity
Scale58 and Clinical Global Impressions-Schizophrenia
scale67 to assess negative symptoms. The duration of
follow-up and frequency of assessment ranged from
6 weeks to 10 years and three to 64 times, respectively.
Five studies19,20,57,61,64 identified four trajectories of
negative symptoms with variable patterns, whereas one
study65 found five trajectories with approximately half of
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Fig. 2 Schizophrenia spectrum circle illustrating the schizophrenia symptoms and cognitive deficits (innermost circle), sample groups (inner circle),
identified trajectories (outer circle) and predictors (outermost circle) in longitudinal studies. Findings are read and interpreted based on the line up in
the circle.
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treatment. The other two studies58,67 found three trajec-
tories with most of the participants had minimally stable
negative symptoms. Our review depicted that trajectories
of negative symptoms were predicted by older age, male
gender, low educational status, ethnic minority, being
unmarried, family history of psychosis, long duration of
untreated psychosis, poor premorbid adjustment, severe
depressive and disorganized symptoms, diagnosis of
schizophrenia, unemployment, poor functioning and
quality of life, high antipsychotics dosage, low cognitive
performance, and high level of baseline negative and
positive symptoms (Fig. 2).
Positive and negative symptoms
Combining both positive and negative symptom
dimensions, which is illustrated in Table 1c, eight stu-
dies17,22,56,57,59,60,62,63 inspected trajectories in patients
with first-episode or chronic schizophrenia with anti-
psychotics treatment for more than three months and all
of these studies used the PANSS scale to measure positive
and negative symptoms. The duration of follow-up and
frequency of assessment ranged from three months to two
years and five to ten times, respectively. Among these
studies, four22,56,60,62 of them revealed five trajectories,
two57,63 of them revealed three trajectories, one study17
found four trajectories and another study59 found two
trajectories with substantial difference in the nature,
pattern and distribution of trajectories. Symptom trajec-
tories were predicted by older age, male gender, ethnic
minority, increased weight, diagnosis with schizophrenia,
late age of illness onset, depressive and extrapyramidal
symptoms, general psychopathology, type of anti-
psychotics treatment (e.g., aripiprazole, olanzapine),
exacerbation, long duration of illness, poor premorbid and
cognitive functioning, low global functioning and quality
of life, living situation, involuntary admission, previous
hospitalization and severe baseline positive and negative
symptoms (Fig. 2).
Cognitive deficits
As shown in Table 1d, three studies investigated the
trajectories of global cognitive deficits in patients with
first-episode psychosis patients, their siblings and healthy
controls52,66, and clinically stable outpatients with schi-
zophrenia (SCZ) together with healthy controls16. The
first six-year longitudinal study52, which cognitive func-
tion was assessed by the cognitive battery test, depicted
five trajectories of cognitive impairment in patients (i.e.,
most of them with mild to moderate deficits) and four
trajectories in healthy siblings (i.e., most of them had
normal cognitive function). The second study66, which
was the follow-up of the previous study, found six cog-
nitive trajectories (i.e., nearly half of the population had
mild to severe cognitive impairment) by combining
patients, siblings and controls. The third longitudinal
study16 have used the Mattis Dementia Rating Scale and
reported three trajectories (i.e., half of them with high and
stable trajectory) of global cognitive function by com-
bining patients and controls. Two studies found that
patients with poor cognitive trajectories had younger age,
low educational status, non-Caucasian ethnicity, lived in a
sheltered facility, low IQ, poor premorbid adjustment,
severe positive and negative symptoms, and low baseline
cognitive performance16,52. Likewise, siblings with poor
cognitive trajectories had younger age, female gender, low
educational status, non-Caucasian ethnicity, low IQ, poor
premorbid adjustment, severe schizotypy, frequent posi-
tive psychotic experience, and low baseline cognitive
performance (Fig. 2)52. One study discovered that poly-
genic risk score for schizophrenia significantly predicted
poor long-term cognitive trajectory in combined samples
of patients, siblings and controls66.
Schizotypy
A single longitudinal study assessed schizotypy in
healthy college students using the Chapman Psychosis
Proneness Scales (CPPS) and found four trajectories, in
which nearly three-fourths of students were categorized as
non-schizotypal68. This study also found that male gender
and a high level of baseline schizotypy significantly pre-
dicted trajectories (Table 1e, Fig. 2).
In summary, when we inspecting the longitudinal
study’s findings shown in Table 1, studies that found the
same number of trajectories were substantially different
concerning participants composition (patient, sibling and
controls), assessment instruments, symptom dimensions,
frequency of assessment, duration of follow-up, methods
used to generate a composite score, data-driven methods
applied, label, proportion, pattern and type of trajectories,
and identified predictors. In addition, there was no link
between the numbers and types of trajectories and the use
of trajectory analysis methods, study population and
symptom dimensions.
Cross-sectional studies
Of the 53 included studies, 34 studies were cross-
sectional (Table 2) that conducted in different groups of
population. The total sample size per study ranged from
62 to 8231 individuals irrespective of participants’ diag-
nostic status. The reported clustering methods were K-
means or non-hierarchical clustering analysis21,53,55,69–76,
Ward’s method or hierarchical analysis77–83, K-means
clustering and Ward’s method18,38,54,84–89, latent class or
profile analysis15,90,91 and two-step cluster analysis92–94.
One study95 identified clusters using a combination of
clinical/empirical and statistical clustering methods. The
model selection criteria or similarity metrics were visual
inspections of the dendrogram, Pearson correlation,
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squared Euclidean distance (i.e., the most common index),
agglomeration coefficients, Dunn index, Silhouette width,
Duda and Hart index, elbow test, variance explained,
inverse scree plot, average proportion of non-overlap,
AIC, BIC, aBIC, Schwarz’s BIC, Lo–Mendell–Rubin
(LMR) test, adjusted LMR and BLRT.
Among the 34 studies (Table 2), 22 stu-
dies18,38,53,54,70,71,75,76,78–82,84,86–88,90–95 reported cognitive
clusters in patients with first-episode, stable or chronic
schizophrenia with or without antipsychotics treatment
and one study54 reported cognitive clusters in unaffected
siblings. Other studies investigated trajectories of negative
symptoms15,85, positive symptoms83, positive and negative
symptoms21,69,77 in patients and positive and negative
schizotypy in a nonclinical population55,72,73,83. Further-
more, two studies75,90 investigate the data-driven clusters
by combining cognitive deficit and negative symptoms.
Details on clusters and correlates of clusters presented per
symptom dimensions as follows.
Positive symptoms
Only one study83 assessed hallucinatory experience in
patients with schizophrenia using Launay–Slade Halluci-
nation Scale-Revised (LSHS-R) and identified three clus-
ters (Table 2a)83. Given this was an explanatory study,
correlates of clusters were not studied.
Negative symptoms
Two studies15,85 reported three clusters of patients with
(chronic)schizophrenia based on the negative symptoms
that assessed by the SANS scale85 and Schedule for the
Deficit Syndrome (Table 2b)15. Identified clusters were
significantly correlated with male gender, ethnic minority,
low educational status, summer season of birth, early age
onset of illness, severity of positive and negative symp-
toms, poor cognitive performance, poor functioning, high
level of general psychopathology, previous hospitalization,
poor premorbid adjustment, social anhedonia and poor
attitude (Fig. 3).
Positive and negative symptoms
Two studies21,77 assessed positive and negative symp-
toms in patients with childhood-onset or first-episode
schizophrenia using the SAPS and SANS scales, respec-
tively and found three clusters, while another study69 used
the PANSS scale and found four clusters (Table 2c).
Reported symptom clusters were characterized as low
positive and negative symptoms, high positive and low
negative, low positive and high negative, and high positive
and high negative though the patterns and distributions of
clusters were different across studies. Identified clusters
were significantly correlated with male gender, low IQ,
poor global functioning, poorer metacognitive ability, and
high level of positive and negative symptoms (Fig. 3).
Cognitive deficits
Of the 22 studies conducted on neurocognitive deficits,
17 studies38,53,70,71,76,78–82,84,90,92–95 found three clusters,
five studies18,75,86,87,91 reported four clusters and one
study88 discovered five clusters among patients (Table
2d). Most studies assessed global cognitive function using
a comprehensive neuropsychological test that included
three to 18 cognitive subtests. Poor cognitive function in
patients was associated with age, gender, non-Caucasian
ethnicity, low socioeconomic and educational status, poor
premorbid adjustment, low premorbid and current IQ,
early age of illness onset, long duration of illness, severe
positive and negative symptoms, poor social cognition,
high antipsychotics dosage, use of second-generation
antipsychotics, and poor functioning and poor quality of
life (Fig. 3). In siblings, one study54 found three cognitive
clusters in unaffected siblings that associated with young
age, low educational status, low IQ, poor premorbid
adjustment and severe positive schizotypy (Table 2d,
Fig. 3)54. One study92 found that polygenic score (PRS) for
schizophrenia, cognition, educational attainment and
attention deficit hyperactivity disorder (ADHD) corre-
lated with cognitive clusters in patients and their unaf-
fected siblings.
Negative symptoms and cognitive deficits
One study89 found three clusters of (out)patients with
stable schizophrenia spectrum disorder by combining
social cognition that assessed by the Mayer-Salovey-
Caruso Emotional Intelligence Test and negative symp-
toms that assessed by the PANSS scale, whereas another
study74 found four clusters in patients by combining
neurocognition that assessed by Continuous Performance
Tests and negative symptom that assessed by the PANSS
scale (Table 2e). Clusters were significantly correlated
with being unmarried, poor self-esteem, low cognitive
(attention, social) performance, stigma, severity of positive
and negative symptoms, poor social functioning and
quality of life, and previous hospitalization (Fig. 3).
Schizotypy
Three studies investigated schizotypy in unaffected first-
degree relatives of patients with schizophrenia55 and
healthy college students72,73 using the CPPS scale and
found four clusters, whereas another study83 found two
clusters based on hallucinatory experience that assessed
by LSHS-R scale in healthy general population (Table 2f).
Schizotypy clusters were significantly associated with
male gender, lack of pleasure experiences, difficulty of
emotional expression, psychotic-like symptoms, severity
of positive and negative schizotypy, depressive, schizoid
and somatic symptoms, poor social and cognitive func-
tioning, substance abuse and poor personality (Fig. 3).
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To summarize, as we observed in longitudinal studies,
cross-sectional studies that found the same number of
clusters were conducted in a different group of samples
and used various assessment instruments and methods of
generating composite scores and clustering. The labeling,
pattern, proportion, and type of clusters were remarkably
different. Generally, three clusters were the most repli-
cated number of clusters and characterized by low (severe
deficits), mixed (intermediate deficits) and high (intact or
normal performance) cognitive function. In addition,
cognitive clustering, such as verbal fluency deficit, verbal
memory and executive function deficit, face memory and
processing deficits, or global cognitive deficits were
revealed. Cross-sectional studies that found the same
number of clusters were largely different in the
characteristics of study population, pattern of identified
clusters, symptom dimensions, methodology of assess-
ment, applied data-driven methods and identified asso-
ciated factors.
Overall, as shown in Table 3, the reviewed studies
reported two to six clusters or trajectories and 58 factors
that linked with identified clusters and/or trajectories
across all study participants and symptom dimensions.
The most common associated factors were old age, male
gender, non-Caucasian ethnicity, low educational status,
late age of illness onset, diagnosis of schizophrenia, sev-
eral general psychopathology and depressive symptoms,
severe positive and negative symptoms, low cognitive
performance, and poor premorbid functioning, quality of
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Fig. 3 Schizophrenia spectrum circle illustrating the schizophrenia symptoms and cognitive deficits (innermost circle), sample groups (inner circle),
identified clusters (outer circle) and correlates (outermost circle) in cross-sectional studies. Findings are read and interpreted based on the line up in
the circle.
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Table 3 Heatmap summary of clusters/trajectories and predictors across study participants, symptom dimensions and
study design.
Parcipants Symptom dimensions Study design



























< 2 years 
follow-up 











Summer season of birth 
Ethnic minority 
Un married marital status 
Low educaonal status 
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Discussion
To our knowledge, this is the first comprehensive sys-
tematic review based on recent cross-sectional and long-
itudinal data-driven studies in positive and negative
symptoms, and cognitive deficits in patients with schizo-
phrenia spectrum disorders, their relatives and healthy
people. Our review has three major findings. First, long-
itudinal trajectory-based studies found two to five positive
and negative symptoms trajectories in patients and four to
six cognitive trajectories in patients, siblings, controls, or
combined samples. Second, cross-sectional cluster-based
studies identified three positive and negative symptoms
clusters among patients and four positive and negative
schizotypy clusters among healthy siblings. Additionally,
three to five cognitive clusters were discovered in patients
and their unaffected relatives. Third, numerous socio-
demographic, clinical and genetic factors that determine
trajectories and/or clusters were identified.
We showed that longitudinal and cross-sectional studies
in patients, their siblings and healthy general population
have inconsistently identified two to five trajectories/
clusters and various predictors across the schizophrenia
symptoms and cognitive deficits. Several shortcomings
across studies may cause this inconsistency. Previous
longitudinal studies did not uniformly research symptoms
and cognitive deficits. For example, only three
Severe disorganized 
symptoms 










Comorbid diseases  
Atypical anpsychoc 
medicaon 
High anpsychocs dosage 
Poor adherence to treatment 
Treatment history 
Severe posive and negave 
symptoms/schizotypy 
Severe posive schizotypy 
Low cognive performance 
Low meta-cognion 
Poor premorbid funconing 
Poor premorbid adjustment 
Poor social adjustment 
Poor quality of life 
Poor social funconing 





Poor global funconing 
This table/map can only be read and interpreted horizontally. For example, five clusters/trajectories were found in both longitudinal and cross-sectional studies
among patients based on schizophrenia symptoms and cognitive deficits [all red boxes]. The same procedure applies to predictors. For example, age found to be the
predictor of clusters/trajectories of schizophrenia symptoms and cognitive deficits in longitudinal and cross-sectional studies among patients and siblings [all red
boxes].
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studies16,52,66 longitudinally investigated cognitive trajec-
tories, but 22 cross-sectional studies investigated cogni-
tive clusters. Utterly, none of the reviewed longitudinal
and cross-sectional studies also validated their model
using empirical methods or comparable statistical meth-
ods though they have used different complex data-driven
methods. Accumulating evidence showed that the num-
ber of classes in the optimal model derived from one
method can be remarkably different compared to the
other method96. Given that these studies were conducted
in patients at a different stage at diagnosis, disease course
or severity of illness and treatment status, the results may
not be expectedly consistent as well. For example, studies
that included only first-episode psychosis, chronic or
stable patients may identify smaller clusters than studies
that included a mixture of patients with first-episode and
chronic psychosis or patients with severe illness. Addi-
tionally, since the reported studies were conducted in
more than 20 countries, the use of different treatment
strategies and assessment methods in different countries
could further confound the assessment of symptoms and
clinical heterogeneity. Obviously, in patients who are
treated, the observed symptoms and cognitive character-
istics are the product of those features that were present
before treatment and the response to treatment. More-
over, the different measurement tools may lead to dis-
crepant results. For instance, the discrepancy of negative
and positive symptoms trajectories (or cross-sectional
clusters) might partly be attributable to the use of a spe-
cific negative (e.g. SANS) and positive (e.g. SAPS) symp-
tom scale or a more general symptom scale (e.g. PANSS)
that included items measuring cognitive or disorganiza-
tion symptoms. Additionally, some studies administered
up to 18 different neuropsychological tests to measure
cognition while others have used as few as two or three
cognitive assessment tests.
We further observed common methodological limita-
tions across studies. Firstly, the reviewed studies included
various groups of participants from different age groups
and ethnicities. Secondly, while the comparison of patient
clusters and trajectories with healthy siblings or controls
could provide an accurate means of disentangling the
heterogeneity and causes of heterogeneity of schizo-
phrenia symptoms, only four studies (three were cross-
sectional studies) examined clusters in siblings. Likewise,
most studies used healthy controls to standardize patients
neurocognitive composite scores, and a few other studies
used controls to compare the distribution of patient
clusters or trajectory groups. Thirdly, substantial differ-
ences between studies were also noted in constructing
composite scores, use of model selection criteria and
method of parameter estimation. Fourthly, we observed
several ways of subtyping and nomenclature for clusters
or trajectories, which may be difficult for clinicians to
translate the evidence in diagnosing and treating diseases.
This is due to the lack of a standard for designing a study
(e.g. adequate sample size), reporting data analysis
approaches and publishing results42.
Generally, we saw that studies conducted in patients
with similar stages of illness (i.e, first-episode, stable,
chronic stage or with or without treatment) and used
similar assessment methods (i.e., SANS, SAPS or PANSS)
showed some level of similarity in results with respect to
identified trajectories and predictors, but studies are lar-
gely different in duration of follow-up, frequency of
assessment and methods used to assess symptoms or
cognition. By the same token, studies that used the similar
data-driven statistical methods showed similarity in the
number of identified trajectories/clusters, but largely dif-
ferent in study population, stage of illness, use of mea-
surement tool, duration of follow-up, frequency of
assessment and identified factors. Moreover, studies with
duration of follow-up less than two years and above two
years showed a similar level of heterogeneity in symptoms
and cognitive deficits and identified predictors. In addi-
tion, a 10-year study with five times assessment showed
similar findings with a 6 week study with every week
assessment on positive symptoms. On the other hand, a 2-
year study with five times assessment identified only two
trajectories. Despite these facts, all studies interestingly
showed heterogeneity of symptoms and cognitive deficits
at various level with “four trajectories” is the most repli-
cated in longitudinal studies and “three clusters” is the
most replicated in cross-sectional studies. Besides, these
studies consistently reported age, gender, ethnicity, edu-
cational status, age of illness onset, diagnosis, general
psychopathology and depressive symptoms, positive and
negative symptoms, cognitive performance, functioning
and quality of life as determinant factors of trajectories
and/or clusters.
In the era of team science and big data, the use of data-
driven statistical methods is becoming increasingly pop-
ular for the analysis of longitudinal repeated measures
(i.e., latent growth mixture models (LGMMs)) and cross-
sectional (i.e., cluster analysis) data (Fig. 4). In our review,
we observed that LGMMs, such as GMM, latent class
growth analysis (LCGA), mixed mode latent class
regression modelling and group-based trajectory model-
ling (GBTM) were commonly used data-driven methods
in longitudinal studies. LGMMs can identify realistic
categories based on temporal patterns of change in out-
come by assuming the existence of latent classes or sub-
groups of subjects exhibiting similarity with regard to
unobserved (latent) variables19,97. LGMMs have four
advantages for modelling longitudinal data. First, they are
flexible and data-driven methods that can accurately
reveal actual heterogeneity. Second, they allow the clas-
sification of individual subjects into latent classes based
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on the largest probability of class membership. Third, they
are sensitive to the pattern of change over time and robust
in the presence of missing data. Fourth, subject-level
predictors can be directly assessed for association with
class membership and hence with different trajectory
subtypes16,19,97. Cluster analysis, which is commonly used
in cross-sectional studies, is also a data-driven approach
for classifying people into homogeneous groups by
determining clusters of participants that display less
within-cluster variation relative to the between-cluster
variation81. Among the reviewed cross-sectional studies,
K-means and Ward’s method clustering analyses were
commonly used alone or in combination. K-means cluster
analysis is a non-hierarchical form of cluster analysis
appropriate when previous evidence or hypotheses exist
regarding the number of clusters in a sample74. On the
other hand, Ward’s method is a hierarchical cluster ana-
lysis aiming to determine group assignment without prior
hypothesis74. It is believed, K-means cluster analysis can
handle larger data sets compared with Ward’s method73.
The results of statistical subtyping approaches, such as
cluster or trajectory analysis depend on mathematical
assumptions, type of data, number of variables or tests,
sample size and sampling characteristics. Therefore, the
models can be unstable and parameter estimates of clin-
ical symptoms may not converge to a consistent set of
subgroups and lack a direct relationship to clinical
reality59,87,98. For example, intermediate clusters and tra-
jectories substantially vary between studies that used the
same cluster or trajectory analysis method87. We advocate
that study results from data-driven methods should be
applicable, comparable, generalizable and interpretable
into clinical practice. As a result, we recommend to
validate models using at least one additional comparable
statistical methods, combine statistical methods of sub-
typing with empirical/clinical methods, or work together
with clinicians to create a common understanding and
clinically relevant clustering or trajectories nomen-
clatures. Furthermore, it is relevant to replicate clusters or
trajectory groups using independent samples, different
assessment tools that measure the same construct, or
different linkage methods38,99. Finally, further studies are
required that focus on longitudinal study design, unaf-
fected siblings, genetic markers and more detailed mea-
sures of brain network function for improving our
understanding of the biological mechanism underlying
heterogeneity of schizophrenia.
Future clinical advances may benefit from the sub-
grouping of patients to implement tailored therapy. In our
review, we observed that several longitudinal studies were
conducted based on drug response. One study found
individuals who treated with aripiprazole had delayed
response56, whereas another study found olanzapine
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Fig. 4 A hypothetical model for driving big multidimensional data towards a personalized selection of treatments in schizophrenia spectrum
disorders. GBTM: Group-based trajectory modeling; LCGA: Latent class growth analysis; CBT: Cognitive behavioural therapy.
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revealed individuals receiving standard treatment, com-
pared to assertive treatment, showed delayed negative
symptom trajectory19. Furthermore, individuals with
substantial cognitive deficit received high dose of anti-
psychotics18,82,87. Subtyping of symptoms and cognitive
deficits can also contribute to uncover the biological basis
of individual symptoms, rather than studying constella-
tion of co-occurring symptoms1. The identified factors
associated with clusters and/or trajectories could be used
for developing a clinical risk prediction model for high-
risk individuals with prodromal symptoms100,101.
Thus far, findings from this review showed that data-
driven approaches could have substantial role to optimize
the efficacy of personalized care by predicting individual
susceptibility to disease, providing accurate assessments
of disease course, contribute to best-choice of early
intervention, and selecting treatments (e.g., anti-
psychotics, cognitive behavioral therapy, social skill
training, family therapy) targeting subgroups of patients
with similar phenotypic or psychosocial characteristics
(Fig. 4)102. When data-driven methods are implemented
on samples/cohorts following different pharmacological
and non-pharmacological interventions, then, we believe
that our proposed model (Fig. 4) can identify individuals
who successfully treated, not treated or even harmed and
who needs further intervention and close follow-up to
protect from unnecessary cost and side effect of medica-
tion(s). Therefore, findings from our review could assist in
the implementation of personalized and preventive stra-
tegies for clinical practice at least in national or
regional level.
Conclusions
Our review indicated a significant heterogeneity in
results and conclusions obtained from both cross-
sectional and longitudinal studies in terms of the num-
ber of group membership for positive and negative
symptoms and cognition as well as factors (predictors)
associated with the group membership. This review also
identified several methodological issues contributing to
the discrepant results. Generally, the longitudinal studies
identified trajectories characterized by progressive dete-
rioration, relapsing, progressive amelioration and stability,
whereas low, mixed (intermediate) and high psychotic
symptoms and cognitive clusters were identified by cross-
sectional studies. Future studies can be more benefited
from data-driven methods if applied based on pharma-
cological and non-pharmacological treatment responses.
The use of empirical methods to distinguish more
homogeneous subgroups of patients along heterogeneous
symptom dimensions has gained traction in the last sev-
eral years and it is an essential step toward implementa-
tion of a more precise prediction of disease risk and
individualized selection of interventions.
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